| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RGA | Common Stock | Options Exercise | $217,364 | +2,324 | +17% | $93.53 | 15,949 | 06 Mar 2024 | Direct | |
| transaction | RGA | Common Stock | Tax liability | $123,993 | -678 | -4.3% | $182.88 | 15,271 | 06 Mar 2024 | Direct | F1 |
| transaction | RGA | Common Stock | Sale | $346,951 | -1,908 | -12% | $181.84 | 13,363 | 06 Mar 2024 | Direct |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RGA | Stock Appreciation Right (right to purchase) 2016 | Options Exercise | $0 | -4,758 | -100% | $0.000000* | 0 | 06 Mar 2024 | Common Stock | 4,758 | $93.53 | Direct | F2 |
| Id | Content |
|---|---|
| F1 | Represents (i) 2,434 shares sold to pay the exercise price the purchase of common stock, and (ii) 678 shares withheld to satisfy Company tax withholding obligations, resulting in a net settlement of 1,646 shares. |
| F2 | SARs grants vest in 25% increments over four years, starting on December 31 of the year of grant. |